Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Natco Pharma Limited (NSE: NATCOPHARM), ISIN INE987B01026 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
NATCOPHARM last traded at ₹804.95 (-0.01%), with a 52-week range of ₹773.60 to ₹1214.65 (as of 6 Nov 2026).
Shareholding as of Dec 2026: promoters 46.22%, FIIs 15.37%, DIIs 10.82%, mutual funds 7.01%.
EquiSense Score (ECS): 46/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.